RT Journal Article
SR Electronic
T1 Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.07.21251098
DO 10.1101/2021.02.07.21251098
A1 Anouck Becker
A1 Georges Pierre Schmartz
A1 Laura Gröger
A1 Nadja Grammes
A1 Valentina Galata
A1 Hannah Philippeit
A1 Jacqueline Weiland
A1 Nicole Ludwig
A1 Eckart Meese
A1 Sascha Tierling
A1 Jörn Walter
A1 Andreas Schwiertz
A1 Jörg Spiegel
A1 Gudrun Wagenpfeil
A1 Klaus Faßbender
A1 Andreas Keller
A1 Marcus M. Unger
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.07.21251098.abstract
AB The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD (NCT02784145) we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients receiving RS (PD + RS), 30 control subjects receiving RS, and 25 PD patients receiving solely dietary instructions. We performed paired-end 100 base pair length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In PD + RS, fecal butyrate concentrations increased significantly and fecal calprotectin concentrations dropped significantly after 8 weeks of RS. Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations calls for long-term studies, also investigating whether RS is able to modify the clinical course of PD.Competing Interest StatementAS is a consultant for SymbioPharm GmbH, Herborn, Germany. The other authors have declared that no competing interests exist.Clinical TrialNCT02784145Funding StatementThis study was funded by the Michael J. Fox Foundation for Parkinson′s Research (Grant ID: 14603) and the German Parkinson Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved the ethics committee of the Medical Association of Saarland, Saarbruecken, Germany and registered under the reference number 189/15.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDate are available upon request via https://bigd.big.ac.cn/gsa-human/ (project PRJCA004296). https://bigd.big.ac.cn/gsa-human